Spyre Therapeutics, Inc. (SYRE)
109.08
+2.43
(+2.28%)
USD |
NASDAQ |
Aug 25, 09:35
Spyre Therapeutics PS Ratio
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| June 28, 2024 | 514.60 |
| June 27, 2024 | 497.09 |
| June 26, 2024 | 511.97 |
| June 25, 2024 | 505.40 |
| June 24, 2024 | 530.36 |
| June 21, 2024 | 527.51 |
| June 20, 2024 | 561.00 |
| June 18, 2024 | 564.50 |
| June 17, 2024 | 556.62 |
| June 14, 2024 | 689.70 |
| June 13, 2024 | 708.31 |
| June 12, 2024 | 809.87 |
| June 11, 2024 | 831.32 |
| June 10, 2024 | 798.71 |
| June 07, 2024 | 736.98 |
| June 06, 2024 | 757.56 |
| June 05, 2024 | 768.94 |
| June 04, 2024 | 746.40 |
| June 03, 2024 | 805.28 |
| May 31, 2024 | 765.00 |
| May 30, 2024 | 745.30 |
| May 29, 2024 | 701.74 |
| May 28, 2024 | 724.29 |
| May 24, 2024 | 721.88 |
| May 23, 2024 | 715.31 |
| Date | Value |
|---|---|
| May 22, 2024 | 778.13 |
| May 21, 2024 | 789.95 |
| May 20, 2024 | 807.03 |
| May 17, 2024 | 827.38 |
| May 16, 2024 | 827.38 |
| May 15, 2024 | 818.19 |
| May 14, 2024 | 860.00 |
| May 13, 2024 | 809.87 |
| May 10, 2024 | 808.34 |
| May 09, 2024 | 770.25 |
| May 08, 2024 | 722.76 |
| May 07, 2024 | 749.46 |
| May 06, 2024 | 782.95 |
| May 03, 2024 | 783.17 |
| May 02, 2024 | 793.89 |
| May 01, 2024 | 741.36 |
| April 30, 2024 | 722.98 |
| April 29, 2024 | 763.69 |
| April 26, 2024 | 734.58 |
| April 25, 2024 | 710.72 |
| April 24, 2024 | 722.10 |
| April 23, 2024 | 749.68 |
| April 22, 2024 | 728.78 |
| April 19, 2024 | 709.40 |
| April 18, 2024 | 778.79 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| AbbVie, Inc. | 7.314 |
| vTv Therapeutics, Inc. | 10.83 |
| BridgeBio Pharma, Inc. | 22.34 |
| Praxis Precision Medicines, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 4.520 |
PS Ratio Related Metrics
| Price to Book Value | 10.06 |
| Price | 109.08 |
| Earnings Yield | -2.00% |
| Market Cap | 9.606B |